Protocol Ledger

NCT04674761 · Phase III · COMPLETED

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Interventional Phase III clinical trial protocol NCT04674761 sponsored by Albireo in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-19 Enrollment: 52 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04674761
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)52 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04674761
Protocol FieldVerified Registry Value
NCT IdentifierNCT04674761
Consolidated Lead SponsorAlbireo
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment52 participants (ACTUAL)
Registered Start Date2021-03-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI